Potential conflict of interest: Calogero Cammà, Raffaele Bruno, Antonio Gasbarrini and Antonio Craxì have received consulting fees from Gilead, Janssen, Roche and MSD. Dr. Bruno also received grants from Gilead, Janssen, MSD, and Roche, and consults for and received grants from AbbVie and Boehringer Ingelheim.
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
Article first published online: 1 APR 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 5, pages 1692–1705, May 2014
How to Cite
Petta, S., Cabibbo, G., Enea, M., Macaluso, F. S., Plaia, A., Bruno, R., Gasbarrini, A., Craxì, A., Cammà, C. and WEF Study Group (2014), Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 59: 1692–1705. doi: 10.1002/hep.27010
The study was funded by 3P Solution. The funding agency was not involved in the study design or its execution, data management or analysis, article preparation or review, or the decision to submit the article for publication.
- Issue published online: 23 APR 2014
- Article first published online: 1 APR 2014
- Accepted manuscript online: 13 JAN 2014 01:48PM EST
- Manuscript Accepted: 4 DEC 2013
- Manuscript Received: 9 AUG 2013
Additional Supporting Information may be found in the online version of this article at the publisher's website.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.